Cancer Research The Future of Cancer Research: Science and Patient Impact  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 51, 1537-1543, March 1, 1991]
© 1991 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blottière, H. M.
Right arrow Articles by Chatal, J.-F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blottière, H. M.
Right arrow Articles by Chatal, J.-F.

A New Tumor-associated Antigen Expressed on Breast Carcinomas, Defined by Monoclonal Antibody BCA 2271

Hervé M. Blottière2, Sylviane Pelhate, Jacques Aubry, Mireille Kremer, Philippe Thedrez, Catherine Sai-Maurel, Jean-Yves Douillard and Jean-François Chatal

INSERM U.211, Faculté de Médecine, 44035 Nantes Cedex, France [H. M. B., S. P., J. A., M. K., P. T., C. S-M., J-Y. D., J-F. C.]; Laboratoire d'Immunologie Moléculaire, Faculté de Pharmacie, Nantes, France [J. A.]; and Centre René Gauducheau, Quai Moncousu, Nantes, France [P. T., J-Y. D., J-F. C.]

After immunization of mice with the human breast carcinoma cell line MCF-7, we produced monoclonal antibody (mAb) BCA 227, which allowed us to characterize a new tumor-associated antigen. This molecule is strongly expressed by well differentiated mammary carcinoma cell lines and by some other tumor cell lines of epithelial origin. Immunohistological study of frozen sections of different tissues and tumors confirmed its expression by tumor cells of epithelial origin, particularly infiltrating duct carcinomas of the breast. The antigen is also expressed, to a lesser extent, by some normal epithelial cells. Its biochemical characterization revealed a Mr 71,000 protein without an N-linked sugar moiety. Six to 40 x 103 binding sites are present on breast tumor cell surfaces. Although mAb BCA 227, which was found to be of the IgG2a isotype, did not mediate antibody-dependent cell-mediated cytotoxicity with either human or mouse effector cells, a 50% inhibition of SK-BR5 tumor growth was obtained in nude mice, suggesting that another mechanism is responsible for this inhibition. Biodistribution studies of radiolabeled F(ab')2 fragments of mAb BCA 227 in tumor-bearing nude mice showed a preferential localization in the tumor. All these data are in favor of the use of mAb BCA 227 as an immunodiagnostic tool for breast cancer.

1 This work was supported by Association pour la Recherche sur le Cancer (ARC), Villejuif, France, and Association Nationale de Valorisation de la Recherche (ANVAR), France.

2 To whom requests for reprints should be addressed, at INSERM U.211, Faculté de Médecine, 1 rue Gaston Veil, 44035 Nantes Cedex, France.

Received 4/16/90. Accepted 12/13/90.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1991 by the American Association for Cancer Research.